Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 760 JPY 2.04% Market Closed
Market Cap: 133.8B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Torii Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Other Long-Term Assets
ÂĄ9.4B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
-4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Long-Term Assets
ÂĄ423.3B
CAGR 3-Years
-1%
CAGR 5-Years
12%
CAGR 10-Years
6%
Daiichi Sankyo Co Ltd
TSE:4568
Other Long-Term Assets
ÂĄ476.6B
CAGR 3-Years
41%
CAGR 5-Years
36%
CAGR 10-Years
12%
Otsuka Holdings Co Ltd
TSE:4578
Other Long-Term Assets
ÂĄ179.6B
CAGR 3-Years
45%
CAGR 5-Years
34%
CAGR 10-Years
15%
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Long-Term Assets
ÂĄ129.9B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
13%
Astellas Pharma Inc
TSE:4503
Other Long-Term Assets
ÂĄ83.4B
CAGR 3-Years
9%
CAGR 5-Years
-4%
CAGR 10-Years
3%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
133.8B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 379.07 JPY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
9.4B JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 9.4B JPY.

What is Torii Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-4%

Over the last year, the Other Long-Term Assets growth was 13%. The average annual Other Long-Term Assets growth rates for Torii Pharmaceutical Co Ltd have been 2% over the past three years , 14% over the past five years , and -4% over the past ten years .

Back to Top